• Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. • Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s. • The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News . • Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. • Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s. • The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News .

Article Summaries:

  • Korsana Biosciences announced it has secured $175 million in funding to advance a preclinical Alzheimer’s disease therapy. The company’s platform enables therapeutic antibodies to cross the blood‑brain barrier, a key challenge in treating neurodegenerative disorders. Korsana’s lead candidate is still in preclinical development, but the investment supports further research and potential clinical testing. Industry peers Roche and AbbVie are also pursuing blood‑brain‑barrier‑penetrating antibodies for Alzheimer’s, indicating growing interest in this therapeutic strategy. The funding round underscores the market’s confidence in Korsana’s technology and its potential to improve drug delivery to the brain.
  • Korsana Biosciences announced it has secured $175 million in new funding to advance a preclinical Alzheimer’s disease therapy that uses a proprietary platform to ferry antibodies across the blood‑brain barrier. The technology aims to improve drug delivery to the brain, a key hurdle in Alzheimer’s treatment development. Korsana’s approach joins a growing cohort of companies, including Roche and AbbVie, that are pursuing similar BBB‑penetrating strategies in clinical trials. The funding will support further preclinical studies and the eventual transition to human trials, positioning Korsana as a notable player in the competitive Alzheimer’s drug pipeline.

Sources: